Summary
We have studied the pharmacokinetics of flecainide after the oral administration of 100 mg to 8 patients without renal impairment and 8 patients with mild to moderate renal failure. Both groups gave comparable results with respect to the peak plasma concentrations and the time to peak. There was a significant correlation between renal flecainide clearance and endogenous creatinine clearance. The elimination half-time in the patients with impaired renal function was significantly longer (19.9, SD 9.9 h) than that in the patients with normal renal function (11.5, SD 4.2 h), but the variability in the elimination half-time in renal failure could not be explained on the basis of the available results.
This is a preview of subscription content, log in via an institution to check access.
References
Anderson JL, Stewart JR, Perry BA, Van Hamersfeld DD, Johnson TA, Conard GJ, Chang SF, Kvam DC. Pitt B (1981) Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 305: 473–477
Becker JU (1984) Bestimmung der Konzentration eines neuen Antiarrhythmikums, Flecainid, im Plasma durch Hochdruckflüssigkeitschromatographie (HPLC): Probenvorbereitung durch Extraktionssäulen. J Clin Chem Clin Biochem 22: 388–393
Bexton RS, Hellestrand KJ, Nathan AW, Spanell RAJ, Camm AJ (1983) A comparison of the antiarrhythmic effects on AV junctional re-entrant tachycardia of oral and intravenous flecainide acetate. Eur Heart J 4: 92–102
Caplin JL, Johnston A, Camm AJ (1983) Changes in “in vitro” serum binding of disopyramide and flecainide acetate after acute myocardial infarction. Br Heart J 49: 298
Conard GJ (1984) Metabolic diposition of flecainide acetate (R-818) in man. In: Bender F, Cronheim G (Hrsg.), Flecainid — Experimentelle Befunde und klinische Erfahrungen, 2 Auflage Gustav Fischer, Stuttgart New York, pp 71–78
Conard GJ, Carlson GL, Frost JW, Ober RE (1979) Human plasma pharmacokinetics of flecainide acetate (R-818), a new antiarrhythmic, following single oral and intravenous dose. Clin Pharmacol Ther 25: 218
Conard GJ, Carlson GL, Frost JW, Ober RE, Leon AS, Hunninghake DB (1976) Human plasma elimination kinetics of R-818, a new antiarrhythmic (abstr.) APhA Academy of Pharmaceutical Sciences, 21st National Meeting, Orlando, Florida, p 106
Conard GJ, Cronheim GE, Klempt HW (1982) Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic in patients. Arzneimittelforsch 32: 155–159
Conard GJ, Carlson GL, Ober RE (1981) Binding of flecainide acetate (R-818) to human plasma proteins in vitro (abstr.). In: APhA Academy of Pharmaceutical Sciences, 31st National Meeting, Orlando, Florida, p 82
Conard GJ, Ober RE (1984) Metabolism of flecainide. Am J Cardiol 53: 41B-51B
Duff HJ, Roden DM, Maffucci RJ, Vesper BS, Conard GJ, Higgins SB, Oates JA, Smith RF, Woosley RL (1981) Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol 48: 1133–1140
Franciosa JA, Wilen M, Weeks CE, Tanebaum R, Kvam DC, Miller AM (1983) Pharmacokinetics and hemodynamic effects of flecainide in patients with chronic low output heart failure. J Am Coll Cardiol 1: 699
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York Basel
Hattingberg von HM, Brockmeier D, Kreuter G (1977) A rotating iterative procedure (RIP) for estimating hybrid constants in multi-compartment analysis on desk computers. Eur J Clin Pharmacol 11: 381–388
Johnston A, Muhiddin KA, Hamer J (1982) Serum protein binding of flecainide. Br J Clin Pharmacol 13: 606P
Johnston A, Warrington S, Turner P (1985) Flecainide pharmacokinetics in healthy volunteers: The influence of urinary pH. Br J Clin Pharmacol 20: 333–338
Lewis GP, Holtzman JL (1984) Interaction of flecainide with digoxin and propranolol. Am J Cardiol 53: 52B-57B
McQuinn RL, Quarforth GJ, Johnson JD, Banitt EH, Pathre SV, Chang SF, Ober RE, Conard GJ (1984) Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab Dispos 12: 414–420
Muhiddin KA, Johnston A, Turner P (1984) The influence of urinary pH on flecainide excretion and its serum pharmacokinetics. Br J Clin Pharmacol 17: 447–451
Tjandra Maga TB, Verbesselt R, Hecken Van A, Melle Van P, Schepper De PJ (1983) Oral flecainide elimination kinetics: Effects of cimetidine. Circulation 68: 416
Vanhaleweyk G, Balakumaran K, Lubsen J, Roelandt J, Hugenholtz PG (1984) Oral flecainide for suppression of ventricular arrhythmias. Cardiology 71: 30–39
Vaughan Williams EM (1984) A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 24: 129–147
Wijk VLM, Kingma JH, Dunselman JM, Gilst WH, Lie KI, Wesseling H (1984) Pharmacokinetics, tolerance and antiarrhythmic efficacy of intravenous flecainide in patients with ventricular arrhythmias and congestive heart failure. Phar Weekbl [Sci] 6: 126
Author information
Authors and Affiliations
Additional information
dedicated to Professor Dr. U. Geßler on the occasion of his 65th birthday
Rights and permissions
About this article
Cite this article
Braun, J., Kollert, J.R. & Becker, J.U. Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. Eur J Clin Pharmacol 31, 711–714 (1987). https://doi.org/10.1007/BF00541300
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541300